Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
RXRX
Upturn stock ratingUpturn stock rating

Recursion Pharmaceuticals Inc (RXRX)

Upturn stock ratingUpturn stock rating
$5.72
Last Close (24-hour delay)
Profit since last BUY2.33%
upturn advisory
Consider higher Upturn Star rating
BUY since 2 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/10/2025: RXRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

8 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $7.14

1 Year Target Price $7.14

Analysts Price Target For last 52 week
$7.14 Target price
52w Low $3.79
Current$5.72
52w High $12.36

Analysis of Past Performance

Type Stock
Historic Profit -70.87%
Avg. Invested days 26
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/10/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.53B USD
Price to earnings Ratio -
1Y Target Price 7.14
Price to earnings Ratio -
1Y Target Price 7.14
Volume (30-day avg) 8
Beta 0.83
52 Weeks Range 3.79 - 12.36
Updated Date 07/11/2025
52 Weeks Range 3.79 - 12.36
Updated Date 07/11/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.8

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -1297.85%

Management Effectiveness

Return on Assets (TTM) -38.51%
Return on Equity (TTM) -86.1%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2016153419
Price to Sales(TTM) 42.37
Enterprise Value 2016153419
Price to Sales(TTM) 42.37
Enterprise Value to Revenue 33.71
Enterprise Value to EBITDA -5.31
Shares Outstanding 426739008
Shares Floating 388515723
Shares Outstanding 426739008
Shares Floating 388515723
Percent Insiders 5.1
Percent Institutions 74.16

ai summary icon Upturn AI SWOT

Recursion Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Recursion Pharmaceuticals Inc. was founded in 2013. It leverages artificial intelligence (AI) and high-throughput screening to discover and develop novel therapeutics. A significant milestone was its partnership with Bayer in 2020. It has evolved from a drug discovery platform to a clinical-stage biotechnology company.

business area logo Core Business Areas

  • Drug Discovery Platform: Recursion operates a technology platform that combines biology, chemistry, automation, and AI to identify potential drug candidates for various diseases. This involves screening millions of potential therapies against cellular models.
  • Drug Development: Recursion advances identified drug candidates through preclinical and clinical development. Their pipeline includes programs in various therapeutic areas, including oncology, neuroscience, and rare diseases.
  • Software Licensing and Partnerships: Recursion licenses their software platform and datasets to other pharmaceutical companies and research institutions, generating revenue through collaborations and partnerships.

leadership logo Leadership and Structure

The leadership team includes Chris Gibson (CEO), and key executives overseeing research, development, and finance. The organizational structure is based on functional departments, with dedicated teams for drug discovery, clinical development, and technology.

Top Products and Market Share

overview logo Key Offerings

  • REC-994: A clinical-stage drug candidate targeting cerebral cavernous malformation (CCM). Recursion is currently undergoing clinical trials. Competitors include companies developing therapies for vascular abnormalities but specific market share data for CCM is not easily available. Revenue from product is currently 0 but has a good projected revenue for the coming years. Competitors are not specifically targeted CCM but work on other vascular problems.
  • Phenix Platform: Recursion's proprietary drug discovery platform utilizing high-content cellular imaging and AI. This is a technology offering, not a drug, and does not have a direct market share in the traditional sense. Instead, its competitive advantage lies in its speed and efficiency in identifying drug candidates. Competitors include companies offering AI-powered drug discovery services, such as Schru00f6dinger (SDGR) and Exscientia (EXAI), but Recursion's specific niche is its focus on phenotypic screening.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is experiencing a growing adoption of AI and machine learning for drug discovery, development, and clinical trials. The trend towards personalized medicine is also driving demand for more targeted therapies.

Positioning

Recursion Pharmaceuticals Inc is positioned as a leader in AI-powered drug discovery, focusing on phenotypic screening and high-content cellular imaging. Its competitive advantage lies in its proprietary technology platform and extensive datasets.

Total Addressable Market (TAM)

The TAM for AI in drug discovery is estimated to be in the tens of billions of dollars, with projections varying depending on the scope and inclusion criteria. Recursion is positioned to capture a portion of this market through its drug development pipeline and software licensing agreements.

Upturn SWOT Analysis

Strengths

  • Proprietary AI-powered drug discovery platform
  • Extensive datasets and high-content cellular imaging capabilities
  • Partnerships with major pharmaceutical companies
  • Clinical-stage drug candidates in multiple therapeutic areas
  • Strong intellectual property portfolio

Weaknesses

  • High research and development expenses
  • Dependence on successful clinical trial outcomes
  • Competition from other AI-powered drug discovery companies
  • Limited revenue generation to date

Opportunities

  • Expansion of drug development pipeline
  • Further partnerships with pharmaceutical companies
  • Application of AI platform to new therapeutic areas
  • Increased adoption of AI in drug discovery
  • Licensing of AI platforms to other companies

Threats

  • Failure of clinical trials
  • Competition from established pharmaceutical companies
  • Changes in regulatory landscape
  • Economic downturn affecting investment in biotechnology
  • Technological obsolescence

Competitors and Market Share

competitor logo Key Competitors

  • EXAI
  • SDGR
  • CRSP
  • LLY

Competitive Landscape

Recursion has a competitive advantage in phenotypic screening and high-content cellular imaging. Compared to the other competitors in the market their AI capabilities may not be as mature.

Growth Trajectory and Initiatives

Historical Growth: The company has grown through strategic collaborations and expanding its drug discovery pipeline. Revenue growth has been present but not in a straight line, with peaks and valleys.

Future Projections: Analyst estimates suggest continued growth in revenue and pipeline development, driven by AI-powered drug discovery. The actual growth rates and numbers are not provided, however.

Recent Initiatives: Recent initiatives include partnerships with pharmaceutical companies, expansion of the drug development pipeline, and advancements in AI platform capabilities.

Summary

Recursion Pharmaceuticals is a clinical-stage biotechnology company using AI to improve drug discovery and development. They are growing in revenue but are not profitable at this time and have high R&D spend. A risk for the company is failure of clinical trials, and also the fact that it does not have many products on the market. Their main strength is the AI platform for drug discovery.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings (SEC)
  • Analyst Reports
  • Financial News Outlets
  • Company Website

Disclaimers:

The data provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Financial data is based on available information and may be subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Recursion Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Salt Lake City, UT, United States
IPO Launch date 2021-04-16
Co-Founder, CEO & Director Dr. Christopher C. Gibson Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 800
Full time employees 800

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.